Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
PVLA
PVLA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
PVLA News
Palvella Publishes Systematic Review on Statins for Porokeratosis
Feb 02 2026
Newsfilter
Palvella Advances QTORIN™ Drug Development, Expected Approval in 2026
Jan 09 2026
Newsfilter
Palvella Advances QTORIN™ Drug Development, Expected Approval in 2026
Jan 09 2026
Globenewswire
Momentus Inc. Shares Surge 57% Following Fuel Tank Development Announcement
Jan 05 2026
Benzinga
Palvella Therapeutics Stock Soars to $114.69 Following Pipeline Developments
Dec 31 2025
NASDAQ.COM
The $100 Club - Did You Get in Early on the Triple-Digit Surge of ABVX, NUTX, BLTE…?
Dec 19 2025
NASDAQ.COM
Palvella Receives FDA Fast Track Designation for QTORIN™ Rapamycin to Treat Angiokeratomas
Dec 16 2025
Newsfilter
Accenture Set to Surge Over 16%? Check Out 10 Leading Analyst Predictions for Tuesday
Dec 16 2025
Benzinga
Palvella Receives FDA Fast Track Designation for QTORIN Rapamycin in Treating Angiokeratomas
Dec 16 2025
NASDAQ.COM
Adagene and Palvella See Gains Following FDA Fast Track Approvals
Dec 16 2025
SeekingAlpha
Palvella Shows 73% Improvement in Phase 2 Study for Skin Condition Treatment
Dec 15 2025
Benzinga
Palvella Reports 73% Improvement in Phase 2 QTORIN™ Trial for Cutaneous Venous Malformations
Dec 15 2025
Globenewswire
Palvella Reports 73% Improvement in Phase 2 Trial of QTORIN™ for Cutaneous Venous Malformations
Dec 15 2025
Newsfilter
Palvella Therapeutics Announces Encouraging Phase 2 Outcomes for QTORIN Rapamycin Gel
Dec 15 2025
NASDAQ.COM
Oklo Analyst Starts Coverage Optimistically; Check Out the Top 4 Initiations for Friday
Dec 05 2025
Benzinga
Stifel Reaffirms Buy Rating for Palvella Therapeutics and Increases Price Target to $145
Nov 24 2025
Benzinga
Show More News
